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that can influence laboratory assays as 
well as the pitfalls of the assays to aid with 
interpretation of results.
References available at www.cmej.org.za
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Cystic fibrosis (CF) is the most common 
autosomal recessive disorder among 
white individuals, and occurs in all South 
African population groups. Recent evidence 
suggests a prevalence of 1 in 2 000 among 
white South Africans and 1 in 12 000 in 
the coloured population. In black South 
Africans carrier frequency estimates have 
been used to project the incidence of 1 in 
4 624 live births.1
Generally, South Africa offers diagnostic 
services and expertise similar to those 
available worldwide for CF patients.2
The genetic defect
CF is caused by mutations in the CF 
transmembrane conductance regulator 
(CFTR) protein, a product of the CFTR 
gene located on chromosome 7. This 
gene encodes a cAMP-regulated chloride 
channel that regulates chloride transport at 
the apical membrane of epithelial surfaces, 
such as the airways, pancreatic ducts, biliary 
tree and sweat ducts.3 Abnormal transport 
of chloride and/or other CFTR-affected 
ions leads to thick, viscous secretions in 
these organs. Consequently, the CF patient 
typically presents with multisystem disease, 
e.g. suppurative lung disease, pancreatic 
insufficiency, multifocal biliary cirrhosis, 
male infertility and high electrolyte loss in 
sweat.4,5 The last mentioned forms the basis 
of the sweat test for the diagnosis of CF.3
Diagnosing CF
Current consensus is that the diagnosis 
of CF should be based on the presence 
of one or more characteristic clinical 
features, a history of CF in a sibling, or 
a positive newborn screening test plus 
laboratory evidence of an abnormality 
in the CFTR gene or protein. This can 
include biological evidence of channel 
dysfunction (abnormal sweat chloride or 
nasal potential difference) or identification 
of a CF disease-causing mutation in each 
copy of the CFTR gene. The vast majority 
of persons with CF are diagnosed based 
on classic signs and symptoms and 
corroborative laboratory results; however, 
in approximately 5 - 10% of patients the 
diagnosis is not clear-cut.6
Role of the laboratory in the 
diagnosis of CF
The laboratory plays a key role in the 
screening, diagnosis and follow-up of 
patients with CF. Screening tests include 
sweat conductivity measurement and 
newborn testing for immunoreactive 
trypsinogen (universal screening is not 
currently done in South Africa). Diagnostic 
tests include mutation analysis, and 
quantitative measurement of sweat chloride 
(the sweat test) – the gold standard. Other 
ancillary tests may also support the diagnosis 
of CF, e.g. faecal elastase and semen analysis. 
In addition, certain features such as chronic 
metabolic alkalosis and acute salt depletion 
may suggest the diagnosis.6
Genetic testing 
Since the discovery of the CFTR gene 
in 1989, it has been possible to use gene 
mutation analysis as an adjunct to sweat 
testing for the diagnosis of CF.3  The most 
common mutation in the white South 
African population is the ΔF508 (delta F508) 
mutation and the most common in the black 
population is the 3120+G→A mutation. Both 
are present in the coloured population.1,2
More than 1 200 mutations and poly- 
morphisms have been identified, and as 
routine screening tests are not able to 
detect all CFTR gene mutations a negative 
genetic test does not ensure a normal CFTR 
genotype.5 Testing profiles may vary, from 
testing for the two most common above-
mentioned mutations, to extended panels, 
including up to 50 of the most frequently 
observed CFTR mutations within 
populations of European origin. Using the 
êF508 only, about 80% of white carriers 
and 67.4% of coloured carriers will be 
identified. About 46% of black CF carriers 
will be detected using the 3120+GàA test.2 
Requesting molecular analysis instead of 
performing a sweat test may confirm a 
diagnosis of CF, but cannot exclude it.1
Sweat testing is a measure of CFTR function 
and therefore remains an essential test for the 
diagnosis of CF, even in the genomic era.3
The sweat test
The measurement of sweat chloride 
concentration remains a pivotal test for the 
diagnosis of CF and needs to be performed 
to established guidelines to prevent pitfalls as 
well as false positive and false negative results. 
Sweat collection is generally performed in 
one of two ways: The Gibson Cooke method 
uses pilocarpine iontophoresis to stimulate 
sweat production, with subsequent collection 
of sweat onto gauze or filter paper for analysis, 
but more recently many laboratories have 
changed to using the Wescor® apparatus. This 
also employs pilocarpine iontophoresis, but 
the sweat is collected into microbore tubing.7 
Both collection methods are followed up 
by quantitative sweat chloride and sodium 
analysis.5
Generally, sweat tests are not performed until 
the subject is more than two weeks of age and 
weighs more than 3 kg. It can be attempted 
in term infants after 7 days of age if clinically 
important, but insufficient sweat collection 
is often a problem.8 Sweat tests should never 
be performed on babies under 48 hours of 
age, as falsely high values may be obtained.7,9 
Testing should be postponed in acutely ill 
patients. If the patient is malnourished or 
dehydrated, has eczema, untreated Addison’s 
disease, ectodermal dysplasia, certain types 
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of glycogen storage disease or untreated 
hypothyroidism, false positive results may 
be obtained. Sweat electrolytes are decreased 
in patients with oedema and during the 
administration of mineralocorticoids, 
resulting in a false negative sweat test. Under 
these circumstances the test should be 
delayed or avoided.5,8-10
Currently the universally accepted reference 
intervals for sweat chloride concentrations 
are: >60 mmol/l is considered diagnostic 
of CF; 40 - 60 mmol/l – borderline; and 
<40 mmol/l – normal.3,8 Some guidelines 
propose additional reference ranges for 
infants up to age 6 months: ≤29 mmol/l – 
CF unlikely; 30 - 59 mmol/l – intermediate; 
≥60 mmol/l – indicative of CF.6
Sweat chloride concentrations >160 mmol/l 
are not physiologically possible and suggest 
specimen contamination or analytical 
error.10 Sweat sodium concentration 
may also be measured. If the difference 
between the sweat sodium and chloride 
concentrations is >20 mmol/l, the test should 
be repeated. Sodium concentrations must 
not be measured in isolation.8 In addition, 
patients with CF usually have a chloride/
sodium ratio >1. While a ratio >1 supports 
the diagnosis of CF, a ratio of <1 does not 
exclude CF and is not recommended for 
interpretation.9,10
Laboratories are required to follow strict 
guidelines with regard to iontophoresis time 
and current, medium of collection, collection 
time, quantitative sweat electrolyte analysis 
and competency testing.8,9 More detail with 
regard to these guidelines may be obtained 
from www.acb.org.uk/docs/sweat.pdf.9
Sweat conductivity
Examples of qualitative screening sweat tests 
currently in use are the Wescor Sweat-Chek® 
and the Nanoduct® conductivity analysers. 
When evaluating sweat conductivity 
results, it should be noted that values are 
approximately 15 mmol/l higher than sweat 
chloride concentration. It is most likely that 
the difference is  caused by the presence 
of unmeasured anions such as lactate and 
bicarbonate.10 Sweat conductivity must 
be regarded as a screening test only, with 
conductivity values >80 mmol/l (expressed 
as sodium chloride equivalent) very likely 
due to CF. All values >50 mmol/l must be 
followed up with quantitative measurement 
of sweat chloride.7,10
Immunoreactive trypsinogen
In South Africa, population screening 
for CF is not currently performed. It is, 
however, possible to identify most CF 
infants during the first days of life by 
measurement of blood immunoreactive 
trypsinogen (IRT) (pancreatic pro-enzyme 
precursor of trypsin) and identification 
of CFTR mutations.4 In countries where 
newborn screening is available, heel-prick 
blood specimens collected on days 2 - 4 
after birth to measure IRT is a primary 
screen.  Babies with increased IRT levels are 
selected for sweat testing and mutational 
analysis. It is thought that pancreatic acini 
in infants with CF are capable of producing 
trypsinogen, but ductules are blocked, 
preventing trypsinogen from reaching 
the small intestine to be converted to 
trypsin, hence leading to ‘spillage’  into the 
circulation. The IRT levels decrease after 
1 - 2 months, indicating that pancreatic acini 
are no longer functioning well enough and 
therefore the IRT test becomes unreliable 
after this period.5
Ancillary tests 
Faecal elastase can be measured to 
assess pancreatic exocrine function. This 
pancreas-specific protease present in the 
pancreatic juice is not degraded during 
passage through the gut. Low faecal elastase 
(<200 μg/g) after 4 weeks of age is indicative 
of pancreatic insufficiency and provides 
supporting evidence for a diagnosis of CF. 
Respiratory tract microbiology (sputum 
or bronchoalveolar lavage) and urogenital 
evaluation (semen analysis) can also be 
useful in the diagnosis of CF.5
Conclusion
CF is a common genetic disease with a 
diverse clinical presentation, and should be 
considered in the differential diagnosis in 
all South African population groups with 
suggestive symptoms. The laboratory plays a 
central role in the diagnosis and follow-up of 
these patients, but clinicians must be aware 
of the limitations, pitfalls and systematic use 
of these tests when interpreting results.
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It is important to differentiate between 
food allergy and other causes of adverse 
reactions to food because patients with 
severe immediate-onset IgE-mediated food 
allergy are at risk of developing anaphylaxis 
that may cause death (Fig. 1).
Up to 35% of the population in Western 
countries self-report ‘food allergies’, but the 
true prevalence is probably between 3% and 
6% in children and 1% and 4% in adults.1 
Approximately 90% of documented cases 
of food allergy in the USA are caused by a 
relatively small number of foods that comprise 
cow’s milk, egg, soy, wheat, peanut, tree nuts, 
fish and shellfish. Food-induced anaphylaxis 
is caused mainly by peanut, followed by tree 
nuts, fish, cow’s milk and egg.
Laboratory investigations
Current food allergy guidelines emphasise 
that a true diagnosis of immediate-onset 
IgE-mediated food allergy requires a 
positive history of clinical allergy to a 
specific food as well as a positive allergy test 
that matches that history.2-4
Any investigation into food allergy has to 
commence with a detailed allergy-focused 
history and examination, followed by a 
selection of appropriate tests to confirm or 
exclude allergy. It is important to distinguish 
between sensitisation (the presence of 
allergen-specific IgE antibodies) and allergy 
